Coronary artery disease (CAD): PCI or CABG in stable CAD, or post STEMI and post non-STEMI, Cardiac rehabilitation , Diabetes Mellitus
Conditions
Interventions
To exclude new diabetics, a fasting plasma glucose will be measured in each patient that meets the inclusion criteria. Patients with a fasting plasma glucose ≥
7.0mmol/l or HbA1c ≥
53 will be referred for further treatment of their diabetes and will not be included in the trial. Patients who meet the inclusion criteria and non of the exclusion criteria will be randomized in a 1:
Sponsors
Isala Klinieken, te Zwolle
Maatschap Cardiologie, Interne en sportgeneeskunde, Isala Klinieken.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Pcoronary artery disease (CAD): PCI or CABG in stable CAD, or post STEMI and post non-STEMI (inclusion within 2 month after admission); 2. Age ≥ 18 years; 3. Elevated HbA1c levels (HbA1c > 5.8% or > 40 mmol/mol) on admission; 4. Access to a computer with internet connection; 5. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Known diabetics, with or without anti-diabetic medication; 2. Contra-indications for Metformine use as stated in the medication registration; 3. Life Expectancy <1 yr; 4. Physical limitations/restrictions for participation in exercise programme or exercise testing; 5. Fasting plasma glucose ≥ 7.0mmol/l or HbA1c ≥ 53.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A 10% reduction in HbA1c at one year in patients with coronary artery disease (PCI or CABG in stable CAD, or post STEMI and post non-STEMI patients) that have pre-diabetes. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. hsCRP; 2. LDL cholesterol; 3. MACE at one year FUP; 4. Exercise capacity. | — |
Contacts
Public ContactSonja Postma
Dokter Stolteweg 96
Outcome results
None listed